- Home
- CATX vs CRDF Comparison
CATX vs CRDF Comparison
Compare CATX & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- CRDF
- Stock Information
- Founded
- CATX 1983
- CRDF 1999
- Country
- CATX United States
- CRDF United States
- Employees
- CATX N/A
- CRDF N/A
- Industry
- CATX Medical/Dental Instruments
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CATX Health Care
- CRDF Health Care
- Exchange
- CATX Nasdaq
- CRDF Nasdaq
- Market Cap
- CATX 239.0M
- CRDF 233.5M
- IPO Year
- CATX N/A
- CRDF N/A
- Fundamental
- Price
- CATX $3.97
- CRDF $4.04
- Analyst Decision
- CATX Strong Buy
- CRDF Strong Buy
- Analyst Count
- CATX 11
- CRDF 6
- Target Price
- CATX $12.90
- CRDF $11.92
- AVG Volume (30 Days)
- CATX 1.3M
- CRDF 1.5M
- Earning Date
- CATX 08-11-2025
- CRDF 08-07-2025
- Dividend Yield
- CATX N/A
- CRDF N/A
- EPS Growth
- CATX N/A
- CRDF N/A
- EPS
- CATX N/A
- CRDF N/A
- Revenue
- CATX $1,471,000.00
- CRDF $587,000.00
- Revenue This Year
- CATX N/A
- CRDF N/A
- Revenue Next Year
- CATX N/A
- CRDF N/A
- P/E Ratio
- CATX N/A
- CRDF N/A
- Revenue Growth
- CATX N/A
- CRDF N/A
- 52 Week Low
- CATX $1.60
- CRDF $2.01
- 52 Week High
- CATX $16.55
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- CATX 61.19
- CRDF 65.93
- Support Level
- CATX $3.33
- CRDF $3.07
- Resistance Level
- CATX $3.69
- CRDF $4.22
- Average True Range (ATR)
- CATX 0.38
- CRDF 0.22
- MACD
- CATX 0.01
- CRDF 0.08
- Stochastic Oscillator
- CATX 64.23
- CRDF 87.35
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.